^
Association details:
| Biomarker: | TET1 mutation |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Published date:
10/17/2019
Excerpt:
…discovery cohort, which included 519 patients across five cancer types: bladder cancer (n = 27), esophagogastric cancer (n = 40), head and neck squamous cell carcinoma (HNSCC) (n = 10), melanoma (n = 148), and NSCLC (n = 294)….TET1-MUT was significantly enriched in patients responding to ICI treatment (Fig (Fig2a)2a) (P = 0.003), indicating that TET1-MUT may be a potential predictive biomarker for ICI treatment.
DOI:
10.1186/s40425-019-0737-3
